This paper analyses the impact of patents on the dynamics of new drug introduction into different national markets. By studying a set of markets for HIV/AIDS drugs in a sample of developing countries, we find that patents only make the introduction of new drugs significantly quicker in the case...

The New Zealand Biotechnology sector is worthy of study for several reasons. While there is a large and growing international literature on economic aspects of biotechnology innovation these studies concentrate on the United States and Europe. The New Zealand biotechnology sector may be expected...

Given the cost of trade and availability of pharmaceuticals, the driving force for parallel trade is the price difference between the source (exporting) and the destination (importing) country. An increase in the price difference or in the availability of pharmaceuticals for parallel trade...

We study effects of direct-to-consumer advertising (DTCA) in a market with two pharmaceutical firms providing horizontally differentiated (branded) drugs. Patients varying in their susceptability to medication are a priori uninformed of available medication. Physicians making the prescription...

We study the relationship between regulatory regimes and pharmaceutical firms’ pricing strategies using a unique policy experiment from Norway, which in 2003 introduced a reference price (RP) system called “index pricing” for a sub-sample of off-patent pharmaceuticals, replacing the...

We consider a therapeutic market with potentially three pharmaceutical firms. Two of the firms offer horizontally differentiated brand-name drugs. One of the brand-name drugs is a new treatment under patent protection that will be introduced, if the profits are sufficient to cover the entry...

What has been the effect of competition from parallel imports on prices of locally-sourced onpatent drugs? Did the 2002 Swedish mandatory substitution reform increase this competition? To answer these questions, we carried out difference-in-differences estimation on monthly data for a panel of...

While there is a large and growing international literature on economic aspects of biotechnology innovation (e.g. work by Carlsson, McKelvey, Orsenigo, Zucker and Darby) these studies concentrate on the United States and Europe. The New Zealand biotechnology industry may be expected to develop...

The New Zealand Government has indicated a strong interest in fostering innovation and aims to concentrate on selected areas where New Zealand may be able to develop a new comparative advantage. One such area is biotechnology, which would build on New Zealand's existing comparative advantage in...

This paper provides a detailed description of the New Zealand biotechnology sector based on a re-analysis of the first comprehensive (1998/99) survey of biotechnology in New Zealand, data from an original (2002) survey conducted by the author and a detailed review of secondary sources. It...